GLP-1 Receptor Agonists in Glaucoma Care

Glaucoma exists at the intersection of vascular dysregulation, metabolic stress, and neurodegeneration.

1

GLP-1 receptor agonists may lower the risk of primary open-angle glaucoma compared to metformin in diabetes patients.
2

These medications exhibit neuroprotective and anti-inflammatory properties that could benefit glaucoma management.
3

GLP-1 receptor agonists may stabilize vascular autoregulation and modulate neuroinflammatory pathways early in glaucoma.
4

The connection between metabolic health and optic nerve health suggests a need for optometrists to consider systemic medications.
5

The emerging metabolic-glaucoma connection represents a significant area for future research and clinical attention.

1